With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers. The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial ...

Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein ...

All told, 89% of those on Lilly's drug achieved a 5% body weight reduction, versus 28% of the placebo arm, with 55% and 1.3% respectively achieving a 20% reduction. "Tirzepatide is the first ...

Eli Lilly has agreed a deal to acquire French antibody-drug conjugate (ADC) specialist Mablink, continuing a series of transactions that build its position in what has become one of the fastest ...

Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...

Eli Lilly and Company (India) Pvt. Ltd. (Lilly India), headquartered in Gurgaon, is a wholly owned subsidiary of Eli Lilly and Company, headquartered in Indianapolis, USA. Lilly has been present ...

Obesity is the most competitive space in biopharma right now. The two frontrunners, Novo Nordisk and Eli Lilly, are locked in a very tight fight for leadership in a market that by some estimates could ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...